You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)創新藥TDI01混懸液獲批塵肺病臨床試驗
阿思達克 03-08 16:38
中生製藥(01177.HK)公布,自主研發的一類創新藥「TDI01」混懸液近日獲得中國國家藥監局批准,開展用於塵肺病的臨床試驗。 集團表示,TDI01是全新靶點、高選擇性的Rho/Rho相關捲曲螺旋形成蛋白激(酉每)2(ROCK2)抑制劑,已在美國完成一期臨床試驗,安全性良好,目前正在國內開展橋接試驗,該產品此前已在國內獲得批准開展特發性肺纖維化的臨床試驗,塵肺病為其第二個獲批開展臨床的適應症。中生製藥表示,將繼續探索其在更多的纖維化及其相關領域的應用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account